Verified· 2 sources

Hartis-Pharma SA

Summary

About the company

The core activity of HARTIS Pharma consists of researching and developing therapeutics based on the potential benefits of High-Density-Lipoprotein (HDL), particularly through the regulation of membrane cholesterol and its liposoluble cargo activity of antioxidants. The company focuses on developing treatments for medical needs that have not been adequately addressed or cannot be treated sufficiently.

AI-generated

Offering

Products & services

Industry:Pharmaceutical Industry

✓ Offered4

Development of therapeutics for sickle cell disease

Development of oral and injectable active ingredients for the treatment of sickle cell disease, including HRT-001 for chronic SCD and HRT-002 for vaso-occlusive crises.

Development of HDL-based therapies

Revisiting the therapeutic potential of HDL to regulate cholesterol in the red blood cell membrane as well as to reduce oxidation and hemoglobin polymerisation.

Development of therapies for sickle cell trait and related pathologies

Investigation of potential therapeutic approaches for sickle cell trait as well as applications in thalassaemia, microcirculation and type 2 diabetes.

Development of antioxidant and lipophilic vitamin transport therapies

Transport of liposoluble vitamins and antioxidants with possible applications in skin conditions, age-related macular degeneration, Alzheimer and neurodegenerative diseases.

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Hartis-Pharma SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

Hartis-Pharma SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

No knowledge articles yet

Hartis-Pharma SA in comparison

Industry comparisons are coming soon

Similar companies